** Shares of healthcare company Organon OGN.N rise 11.2% to $16.34
** The developer of drugs for women's health and biosimilars posts Q4 adjusted profit of 90 cents per share vs analysts' average estimate of 87 cents per share - data compiled by LSEG
** Q4 revenue at $1.59 billion, in line with the estimate
** "We expect a slightly positive stock reaction on Q4 EPS beat and better EBITDA guidance, as the revenue guidance was materially impacted by FX," says brokerage BNP Paribas Exane
** Company forecasts 2025 revenue in the range of $6.13 billion to $6.33 billion, below analysts' estimate of $6.47 billion
** OGN shares down ~3% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。